 SALT LAKE CITY, Feb. 11, 2021 GLOBE NEWSWIRE -- Myriad Genetics, Inc. NASDAQ: MYGN, a leader in genetic testing and precision medicine, announced today that it will participate at multiple upcoming health and technology conferences, sharing insights on how the company is intensifying its focus on serving patients and healthcare providers in Womens Health, Oncology and Mental Health. 